Volume 1 Issue 3
Plasma cell leukemia
Shira Shoher, Shay Yeganeh, Arnon Blum*
Monoclonal gammopathies comprise a wide range of entities characterized by the clonal proliferation of plasma cells (PC’s) which are terminally differentiated B cells. They are characterized by the secretion of electrophoretic ally and immunologically homogeneous (monoclonal) proteins. When the number of circulating PCs is significant, the term plasma cell leukemia (PCL) is usually used. Whereas monoclonal gammopathy of undetermined significance (MGUS) is the most common form of PC’s gammopathy, PCL is a rare entity, comprises only 2 % of patients with plasma cell neoplasm’s.
Rare Presentation of Anaplastic Large Cell Lymphoma and HTLV1 Positivity: A Case Report and Review
Anaplastic large cell lymphoma (ALCL) is a biologic and clinically heterogeneous subtype of T-cell lymphoma, which may present as localized (primary) cutaneous disease or widespread systemic disease. Primary cutaneous ALCL (C-ALCL) is part of a spectrum of CD30+ lymphoproliferative diseases of the skin with excellent prognosis. HTLV-1-associated lymphomas include adult T-cell lymphoma and leukemia (ATL), which is characterized by a clonal expansion of CD4+ T lymphocytes frequently associated with skin rash, lymph node and visceral involvement, and hypercalcemia. ATL rarely resembles ALCL and CD30 positive.
P-Selectin as a Platelet Activation Marker and Cardiovascular Risk Prediction Factor. Differences between its Two Isoforms Using Flow Cytometry and Elisa Analyses
Romanelli G*, Olivera-Bravo S, Santiñaque FF, Soto E, Javiel G, López-Carro B, Folle GA, Mimbacas A
Cardiovascular diseases are the main cause of death in developed countries. Twenty seven percent of total deaths were caused by cardiovascular diseases, according to 2012. Uruguayan Health State Department reports. Diabetes mellitus (DM) is frequently associated with vascular complications. DM patients have 2 to 4 times more probabilities to suffer macrovascular diseases and DM abnormal metabolic conditions are responsible for changes leading to atherosclerosis.
Botanic Selective Estrogen Receptor Modulators (SERMs) and Venous Thrombo Emboli (VTE)
Arnon Blum*, Shira Shoher, Andrei Adler, Doron Ben David, Shay Yeganeh
Estrogens are widely used as relieving agents for women suffering from postmenopausal symptoms. In order to prevent side effects of estrogens (breast or uterine cancer) and promote desirable effects (preventing osteoporosis and atherosclerosis) selective estrogenic receptor modulators [SERM’s] were developed. Botanical SERMs are considered beneficial and safe. We would like to describe a 56 years old woman who got a botanic SERM (marketed as an over the counter food supplement) and was admitted with fever and occlusion of the portal venous system.
Essential Thrombocythemia and Fibroblast Growth Factor-2: Role of Anagrelide
Rossella Cacciola*, Elio Gentilini Cacciola, Emma Cacciola
Evolution into myelofibrosis is part of the natural history of the essential thrombocythemia (ET). The myelosuppressive therapy in ET may itself increase the risk of transformation to myelofibrosis. The challenge in treating ET is to prevent this risk. It is reported that activated thrombocythemic platelets release fibroblast growth factor-2 (FGF-2). Anagrelide (ANA) is a myelosuppressive agent that inhibits the platelet function. The major concern regarding ANA is whether it do not increase the putative risk of transformation to myelofibrosis. In this study we report the results of a randomized group of patients with ET in treatment with ANA that after a follow-up of 5 years showed a reduction in the myelofibrosis. A likely explanation for this finding is the broader activity of ANA which also affects the platelet function.
Two Cases with Essential Thrombocytopenia Transforming to Acute Myeloid Leukemia within a Short Time
Osman Yokuş, Habip Gedik*
Myeloproliferative neoplasms (MN) are inclined to be transformed into acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS) by losing the ability of differentiation as a result of neoplastic proliferation of hematopoietic cells with additional factors such as chromosome abnormalities and disorders of intracellular in time. Two cases with essential thrombocythemia (ET) transforming into AML within a short time are being presented for evaluation with current literature. Blastic transformation and acute leukemia should be taken into consideration and be examined in cases who have ET, leukocytosis, constitutional symptoms, decline in other cell lines, splenomegali at follow-up. If appropriate donor is found for transplantation, it should be planned after remision is obtained. Since prognosis is usually poor.